검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | NY-ESO-1 (157-165, NY-ESO-1, NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine) USWM CT, LLC·Adult Solid Neoplasm 55 trials |
|---|---|
Overview Program | NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine |
Overview Company | USWM CT, LLC |
Overview Modality | ANTIBODY |
Overview Target | Adult Solid Neoplasm |
Overview Indication | Adult Solid Neoplasm; Childhood Solid Neoplasm |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targeting a well-known immunogenic cancer antigen |
MoA Biomarker | biomarkers of resistance |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.. The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib delays disease progression in dedifferentiated liposarcoma (DDLPS) by inducing tumor cell quiescence or senescence, though most tumors ultimately progress. Preclinical data suggest CDK4/6 inhibition enhances intratumoral inflamma… |
Toxicology CRS | Reported |
Clinical PFS | 0.78 |
Clinical Result source | ClinicalTrials.gov NCT02166905 |
Clinical Data Tier / Score | A · 32 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | NY-ESO-1 (157-165, NY-ESO-1, NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine) USWM CT, LLC·Adult Solid Neoplasm 55 trials |
|---|---|
Overview Program | NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine |
Overview Company | USWM CT, LLC |
Overview Modality | ANTIBODY |
Overview Target | Adult Solid Neoplasm |
Overview Indication | Adult Solid Neoplasm; Childhood Solid Neoplasm |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targeting a well-known immunogenic cancer antigen |
MoA Biomarker | biomarkers of resistance |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.. The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib delays disease progression in dedifferentiated liposarcoma (DDLPS) by inducing tumor cell quiescence or senescence, though most tumors ultimately progress. Preclinical data suggest CDK4/6 inhibition enhances intratumoral inflamma… |
Toxicology CRS | Reported |
Clinical PFS | 0.78 |
Clinical Result source | ClinicalTrials.gov NCT02166905 |
Clinical Data Tier / Score | A · 32 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교